Published in Healthcare Mergers, Acquisitions and Ventures Week, March 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Neopharm.
Report 1: Neopharm, Inc. (NEOL) announced that the pivotal Phase III PRECISE trial evaluating cintredekin besudotox (IL13-PE38QQR) for the treatment of recurrent glioblastoma multiforme did not meet the efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer.
"Topline data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.